Arbor Biotechnologies
PrivateLast Round
Series C
Mar 18, 2025
Est. Valuation
$575M
Total Funding Raised
$320.1M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Arbor Biotechnologies is a biotechnology company that develops genomic medicines and gene-editing tools using AI and machine learning to address genetic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Arbor Biotechnologies Comparables
Compare Arbor Biotechnologies with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Scribe Therapeutics | 85% | |
| Tessera Therapeutics | 79% | |
| HuidaGene Therapeutics | 79% |
Arbor Biotechnologies Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Mar 18, 2025 | ||||
| Series B | Nov 9, 2021 | ||||
| Series A | Aug 2, 2017 | ||||
| Series A | Jun 1, 2017 |
Key People
Founding team and executive leadership
Arbor Biotechnologies Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| GreatPoint Ventures | Series B |
| S32 | Series B |
| Surveyor Capital | Series C, Series B |
| Janus Henderson Group | Series B |
| Aberdeen Group plc | Series C |
| Temasek | Series C, Series B |
| TCG Crossover | Series C, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 17, 2026
Monthly visitors increased 79% MoM.
- Mar 1, 2026
Lead program ABO-101 enters clinical trials for primary hyperoxaluria type 1.
Arbor Biotechnologies Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Arbor Biotechnologies's valuation, stock price, and market status.
Is Arbor Biotechnologies a public or private company?
Arbor Biotechnologies is a private company.
What is the current stock price of Arbor Biotechnologies?
Arbor Biotechnologies is a private company with no public stock price. No recent secondary market data is available.
How much is Arbor Biotechnologies worth (valuation)?
Valuation information for Arbor Biotechnologies is not publicly available.
Can I buy Arbor Biotechnologies stock?
Arbor Biotechnologies shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Arbor Biotechnologies's last funding round?
Arbor Biotechnologies's most recent funding round was Series C on March 18, 2025.
Who are the main investors in Arbor Biotechnologies?
Key investors in Arbor Biotechnologies include TCG Crossover, Ally Bridge Group, ARCH Venture Partners, ARCH Venture Partners.
Will Arbor Biotechnologies IPO soon?
No public IPO plans have been announced for Arbor Biotechnologies.
How can I track Arbor Biotechnologies secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Arbor Biotechnologies's secondary market activity and sign up for updates.